Keros Therapeutics Inc
KROS16.200USD
+0.030+0.19%
收盤 11/07, 16:00（美東）報價延遲15分鐘
658.24M總市值
10.21本益比TTM
關於 Keros Therapeutics Inc 公司
Keros Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化新型療法，以治療一系列與轉化生長因子-β (TGF-B) 蛋白家族信號傳導功能障礙相關的疾病患者。該公司的主要候選產品 KER-050 正在開發中，用於治療骨髓增生異常綜合徵患者和骨髓纖維化患者的低血細胞計數或血細胞減少症（包括貧血和血小板減少症）。該公司的第二個候選產品 KER-012 正在開發中，用於治療肺動脈高壓 (PAH) 和心血管疾病。該公司的第三個候選產品 KER-065 正在開發中，用於治療肥胖症和神經肌肉疾病。KER-050 旨在通過抑制 TGF-B 蛋白家族子集的信號傳導來促進造血，從而增加紅細胞和血小板的生成。
Keros Therapeutics Inc簡介
公司代碼KROS
公司名稱Keros Therapeutics Inc
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
員工數量169
證券類型Ordinary Share
年結日Apr 08
公司地址1050 Waltham Street, Suite 302
城市LEXINGTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02421
電話16173146297
網址https://www.kerostx.com/
公司代碼KROS
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Keros Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月18日 週六
更新時間: 10月18日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.89%
Madison Avenue Partners LP
8.83%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.85%
Logos Global Management LP
6.56%
其他
59.93%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.89%
Madison Avenue Partners LP
8.83%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.85%
Logos Global Management LP
6.56%
其他
59.93%
股東類型
持股股東
佔比
Hedge Fund
28.22%
Investment Advisor
20.16%
Investment Advisor/Hedge Fund
16.87%
Venture Capital
5.08%
Research Firm
4.48%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
1.35%
Pension Fund
1.12%
其他
18.79%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
385
41.03M
124.11%
-17.81M
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
2.62M
6.45%
+53.89K
+2.10%
Jun 30, 2025
Madison Avenue Partners LP
2.69M
6.63%
+77.06K
+2.95%
Jun 30, 2025
Tang Capital Management, LLC
1.42M
3.49%
+318.98K
+29.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
5.88%
-118.03K
-4.71%
Jun 30, 2025
Logos Global Management LP
2.00M
4.92%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.62M
3.99%
+113.90K
+7.56%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.30M
3.19%
+34.25K
+2.71%
Jun 30, 2025
Western Standard, LLC
1.53M
3.78%
+1.40M
+1037.68%
Jun 30, 2025
State Street Investment Management (US)
1.38M
3.41%
+81.72K
+6.27%
Jun 30, 2025
OrbiMed Advisors, LLC
1.02M
2.51%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
ALPS Medical Breakthroughs ETF
0.38%
Federated Hermes MDT Small Cap Core ETF
0.21%
SPDR S&P Biotech ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
iShares Biotechnology ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.84%
ALPS Medical Breakthroughs ETF
佔比0.38%
Federated Hermes MDT Small Cap Core ETF
佔比0.21%
SPDR S&P Biotech ETF
佔比0.18%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
WisdomTree US SmallCap Quality Growth Fund
佔比0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
iShares Biotechnology ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
